NCT05391425|UnknownDMC
Loading search results
Sponsor study identifier
observational
150
1 country
1
Study Start
June 3, 2021
Actual (reported)Primary Completion
June 3, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 3, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 3, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 3, 2021
Actual (reported)May 17, 2022
Actual (reported)May 26, 2022
Actual (reported)June 3, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 3, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
the effect of solifenasin used for lower urinary tract symptoms on sexual function
Female Sexual Function Index (FSFI) scores change between in baseline, 3 and 6 months after Solifenacin use for lower urinary tract symptoms.
6 months
the effect of solifenasin used for lower urinary tract symptoms on sexual function in premenapausal vs postmenapausal women
The aim of this study is to determine whether Solifenacine used for lower urinary tract symptoms improve sexual function (measured by Female Sexual Function Index; higher scores meaning sexual dysfunction with the cut off value of 26.) and if so does this improvement differs between premenaupausal and postmenaupausal women.
6 months
the effect of Solifenacin treatment for lower urinary tract symptoms (LUTS) on sexual function and its correleation with the improvement in LUTS
3 and 6 months
Premenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
Postmenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
no intervention planned, since it is an observational study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg) are enrolled in the study.
Arnavutkoy State Hospital
Istanbul, Arnavutkoy, 34275, Turkey (Türkiye)
First Submitted
May 17, 2022
First Posted
May 26, 2022
Study Start
June 3, 2021
Actual (reported)Primary Completion
June 3, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Effect of Core Muscle Endurance on Punch Speed and Force in Boxers
Contact the study team to confirm eligibility.
Study Completion
June 3, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 26, 2022
Record last verified: 2022-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: